TAYSHA GENE THERAPIES INC (TSHA)
US8776191061 - Common Stock
Overall TSHA gets a fundamental rating of 2 out of 10. We evaluated TSHA against 561 industry peers in the Biotechnology industry. Both the profitability and financial health of TSHA have multiple concerns. TSHA does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year TSHA was profitable.
In the past year TSHA has reported a negative cash flow from operations.
TSHA had negative earnings in each of the past 5 years.
In the past 5 years TSHA always reported negative operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of -12.64%, TSHA belongs to the best of the industry, outperforming 85.77% of the companies in the same industry.
TSHA has a better Return On Equity (-25.65%) than 81.62% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.64% | ||
| ROE | -25.65% | ||
| ROIC | N/A |
ROA(3y)-92.53%
ROA(5y)N/A
ROE(3y)-6259.12%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TSHA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
TSHA does not have a ROIC to compare to the WACC, probably because it is not profitable.
TSHA has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, TSHA has an improved debt to assets ratio.
2.2 Solvency
TSHA has an Altman-Z score of -2.53. This is a bad value and indicates that TSHA is not financially healthy and even has some risk of bankruptcy.
TSHA has a Altman-Z score (-2.53) which is in line with its industry peers.
TSHA has a Debt/Equity ratio of 0.48. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.48, TSHA is doing worse than 73.69% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.48 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.53 |
ROIC/WACCN/A
WACC10.99%
2.3 Liquidity
A Current Ratio of 5.51 indicates that TSHA has no problem at all paying its short term obligations.
TSHA's Current ratio of 5.51 is in line compared to the rest of the industry. TSHA outperforms 58.02% of its industry peers.
A Quick Ratio of 5.51 indicates that TSHA has no problem at all paying its short term obligations.
TSHA has a Quick ratio (5.51) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.51 | ||
| Quick Ratio | 5.51 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 155.75% over the past year.
TSHA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -30.95%.
EPS 1Y (TTM)155.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.08%
Revenue 1Y (TTM)-30.95%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-62.33%
3.2 Future
Based on estimates for the next years, TSHA will show a very negative growth in Earnings Per Share. The EPS will decrease by -34.21% on average per year.
The Revenue is expected to grow by 55.85% on average over the next years. This is a very strong growth
EPS Next Y-396.23%
EPS Next 2Y-123.12%
EPS Next 3Y-74.13%
EPS Next 5Y-34.21%
Revenue Next Year-42.96%
Revenue Next 2Y-41.37%
Revenue Next 3Y-31.03%
Revenue Next 5Y55.85%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
TSHA is valuated cheaply with a Price/Earnings ratio of 3.25.
Based on the Price/Earnings ratio, TSHA is valued cheaper than 99.10% of the companies in the same industry.
TSHA is valuated cheaply when we compare the Price/Earnings ratio to 27.48, which is the current average of the S&P500 Index.
TSHA is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 3.25 | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as TSHA's earnings are expected to decrease with -74.13% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-123.12%
EPS Next 3Y-74.13%
5. Dividend
5.1 Amount
TSHA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TAYSHA GENE THERAPIES INC
NASDAQ:TSHA (1/6/2025, 4:17:13 PM)
After market: 2.0895 +0.04 (+1.93%)2.05
+0.13 (+6.77%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners78.11%
Inst Owner Change0%
Ins Owners1.19%
Ins Owner Change6.89%
Market Cap420.13M
Analysts83.53
Price Target6.57 (220.49%)
Short Float %12.95%
Short Ratio4.34
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)20.27%
Min EPS beat(2)-5.87%
Max EPS beat(2)46.41%
EPS beat(4)3
Avg EPS beat(4)242.72%
Min EPS beat(4)-5.87%
Max EPS beat(4)919.96%
EPS beat(8)5
Avg EPS beat(8)124.82%
EPS beat(12)7
Avg EPS beat(12)84.69%
EPS beat(16)7
Avg EPS beat(16)46.43%
Revenue beat(2)1
Avg Revenue beat(2)-26.35%
Min Revenue beat(2)-59.07%
Max Revenue beat(2)6.37%
Revenue beat(4)3
Avg Revenue beat(4)2.8%
Min Revenue beat(4)-59.07%
Max Revenue beat(4)33.33%
Revenue beat(8)6
Avg Revenue beat(8)56.28%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.61%
PT rev (3m)0.55%
EPS NQ rev (1m)0%
EPS NQ rev (3m)18.91%
EPS NY rev (1m)0%
EPS NY rev (3m)2.09%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-26.92%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.31%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 3.25 | ||
| Fwd PE | N/A | ||
| P/S | 42.37 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 4.73 | ||
| P/tB | 4.73 | ||
| EV/EBITDA | N/A |
EPS(TTM)0.63
EY30.73%
EPS(NY)-0.39
Fwd EYN/A
FCF(TTM)-0.39
FCFYN/A
OCF(TTM)-0.39
OCFYN/A
SpS0.05
BVpS0.43
TBVpS0.43
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.64% | ||
| ROE | -25.65% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-92.53%
ROA(5y)N/A
ROE(3y)-6259.12%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.06
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.48 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 30.34% | ||
| Cap/Sales | 3.98% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.51 | ||
| Quick Ratio | 5.51 | ||
| Altman-Z | -2.53 |
F-Score3
WACC10.99%
ROIC/WACCN/A
Cap/Depr(3y)1722.35%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)155.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.08%
EPS Next Y-396.23%
EPS Next 2Y-123.12%
EPS Next 3Y-74.13%
EPS Next 5Y-34.21%
Revenue 1Y (TTM)-30.95%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-62.33%
Revenue Next Year-42.96%
Revenue Next 2Y-41.37%
Revenue Next 3Y-31.03%
Revenue Next 5Y55.85%
EBIT growth 1Y-11.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-26.25%
EBIT Next 3Y33.92%
EBIT Next 5YN/A
FCF growth 1Y53.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y44.87%
OCF growth 3YN/A
OCF growth 5YN/A